Πέμπτη 23 Ιανουαρίου 2020

Modulation of Nqo1 Activity Intercepts Anoikis Resistance and Reduces Metastatic Potential of Hepatocellular Carcinoma.

Modulation of Nqo1 Activity Intercepts Anoikis Resistance and Reduces Metastatic Potential of Hepatocellular Carcinoma.:

Related Articles
Modulation of Nqo1 Activity Intercepts Anoikis Resistance and Reduces Metastatic Potential of Hepatocellular Carcinoma.

Cancer Sci. 2020 Jan 22;:

Authors: Shimokawa M, Yoshizumi T, Itoh S, Iseda N, Sakata K, Yugawa K, Toshima T, Harada N, Ikegami T, Mori M

Abstract

The processing of intracellular reactive oxygen species (ROS) by nuclear factor erythroid-derived 2-like 2 (Nrf2) and NADPH quinone oxidoreductase 1 (Nqo1) is important for tumor metastasis. However, the clinical and biological significance of Nrf2/Nqo1 expression in hepatocellular carcinoma (HCC) remains unclear. We aimed to clarify the clinical importance of Nrf2/Nqo1 expression in HCC and evaluate the association of Nrf2/Nqo1 expression with HCC metastasis. We also evaluated the impact of Nqo1 modulation on HCC metastatic potential. We used spheroids derived from HCC cell lines. In anchorage-independent culture, HCC cells showed increased ROS, leading to the up-regulation of Nrf2/Nqo1. Futile stimulation of Nqo1 by β-lapachone induces excessive oxidative stress and dramatically increased anoikis sensitivity, finally diminishing the spheroid formation ability; which was far stronger than depletion of Nqo1. We analyzed 117 cases of primary HCC who underwent curative resection. Nrf2/Nqo1 overexpression in primary HCC was associated with tumor size, high alpha-fetoprotein and des-gamma-carboxy-prothrombin levels. Nrf2/Nqo1 overexpression was associated with multiple intrahepatic recurrences (P = 0.0073) and was an independent risk factor for poor prognosis (P = 0.0031). Nqo1 plays an important role in anchorage-independent survival, which is essential for survival for circulation and distant metastasis of HCC cells. These results suggesting that targeting Nqo1 activity may be a potential strategy for HCC adjuvant therapy.

PMID: 31968140 [PubMed - as supplied by publisher]

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου